Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07629167 · ClinicalTrials.gov registry record · Phase 2

Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

A Phase 2 study, sponsored by University of California, San Francisco.

Not yet
Registry status
Phase 2
Development phase
50
Enrollment target

NCT07629167: Clinical Trial Phase 2 study, sponsored by University of California, San Francisco.

NCT07629167 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07629167, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Francisco.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target

Study Summary

A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.

Primary Outcome

The proportion of participants who experience a Grade \< 2 acneiform rash at week 12 while receiving non-investigational treatment for cancer that targets the mitogen activated protein kinase (MAPK) pathway as classified by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0) and 95% confidence interval will be reported.

Interventions

  • BEHAVIORAL Questionnaires
  • DRUG Doxycycline
  • DRUG Isotretinoin
  • PROCEDURE Blood specimen collection
  • OTHER Photographs of Rash

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-08-30
Est. Completion 2030-03-30
Phase Phase 2

What is known before NCT07629167 opens enrollment

NCT07629167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 5 interventions - of which Questionnaires is the first listed.

NCT07629167 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07629167 about?

NCT07629167 is a clinical study titled "Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway". A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.

What is the current status of trial NCT07629167?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-08-30. Estimated completion is 2030-03-30.

What interventions are being tested in trial NCT07629167?

The interventions under investigation include: Questionnaires (BEHAVIORAL), Doxycycline (DRUG), Isotretinoin (DRUG), Blood specimen collection (PROCEDURE), Photographs of Rash (OTHER).

Who is sponsoring clinical trial NCT07629167?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07629167's enrollment target sits among peer trials

50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07629167, the US trial registry maintained by the National Library of Medicine. NCT07629167 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.